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Abstract
Development of compounds that target both heparanase and selectins is emerging as a promising approach for
cancer therapy. Selectins are vascular cell adhesion molecules that mediate tumor cell interactions with platelets,
leukocytes, and the vascular endothelium. Heparanase is an endoglycosidase that degrades heparan sulfate in the
tumor microenvironment, cell surfaces, and vessel wall. Acting together, these molecules facilitate tumor cell
arrest, extravasation, and metastasis. Here, we report the preparation of novel semisynthetic sulfated tri mannose
C-C–linked dimers (STMCs) endowed with heparanase and selectin inhibitory activity. The P-selectin specificity of
the STMC was defined by the anomeric linkage of the C-C bond. This STMC hexasaccharide is an effective inhibitor
of P-selectin in vivo. We show that selective inhibition of heparanase attenuates metastasis in B16-BL6 melanoma
cells, expressing high levels of this endoglycosidase, but has no effect on the metastasis of MC-38 carcinoma cells
that express little or no heparanase activity. P-selectin–specific STMC attenuated metastasis in both animal mod-
els, indicating that inhibition of tumor cell interaction with the vascular endothelium is critical for cancer dissem-
ination. Thus, the small size, the stability of the C-C bond, and the chemically defined structure of the newly
generated STMCs make them superior to heparin derivatives and signify STMCs as valuable candidates for fur-
ther evaluation.
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Introduction
The control of cancer metastasis remains the major obstacle in treat-
ment of cancer patients. Metastasis is a multiple-step process encom-
passing tumor cell release from primary sites, their survival in the
circulation, and extravasation in distant tissues [1]. Metastasis is de-
termined by the cellular origin, intrinsic features of the tumor, and
the adhesive properties of tumor cells.
Heparanase, the only mammalian endoglycosidase that cleaves
heparan sulfate (HS), is upregulated in essentially all human tumors
examined [2–7]. A causal involvement of heparanase in tumor me-
tastasis was demonstrated by increased lung, liver, and bone coloni-
zation of cancer cells after overexpression of the heparanase gene and
by a marked decrease in metastatic potential of cells subjected to
Abbreviations: STMC, sulfated tri mannose C-C–linked dimer
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heparanase gene silencing [8,9]. Moreover, inhibition of heparanase
resulted in attenuation of metastasis in a number of animal models
[8–12]. A significant role of heparanase in tumor angiogenesis and
lymphangiogenesis was demonstrated, applying similar experimental
approaches [2,7,13]. Clinically, increased heparanase levels are most
often associated with increased tumor metastasis, high microvessel den-
sity, and reduced patients’ survival time after operation [2–4,6,14,15].
In another set of studies, the adhesive properties of tumor cells to
vascular cell adhesion molecules, selectins, have been shown to me-
diate tumor cell interaction with platelets, endothelium, and leuko-
cytes. Inhibition of selectin-mediated tumor cell interaction with
blood constituents resulted in attenuation of tumor metastasis in a
number of animal models [16–20].
Several laboratories, including ours, are developing heparin-mimicking
compounds that compete with HS and thereby inhibit heparanase
and selectin prometastatic activities [10,21–23]. Heparin has long
been known to possess antiheparanase activity [24] and to effec-
tively inhibit P- and L-selectins [25,26]. Results from several clin-
ical trials using unfractionated heparin and low-molecular-weight
heparin (LMWH) in preventing thromboembolic complication in
advanced stage cancer patients indicated that heparin prolonged
survival [27] probably owing to a direct effect on the tumor, po-
tentially through inhibition of heparanase enzymatic activity [28].
However, the use of heparin or LMWH as anticancer agents is lim-
ited because of the risk of inducing adverse bleeding complications.
Moreover, heparin exhibits a number of biologic activities including
inhibition of thrombin generation [29], release of tissue factor path-
way inhibitor from endothelial surfaces [30], modulation of growth
factors’ receptor binding and activity [31], affecting angiogenesis
[32], heparanase enzymatic activity [33], and selectin-mediated cell
interactions [34,35]. Despite a significant progress in the analysis of
heparin activities affecting cancer progression, there is a need for a
synthetic small molecule inhibitor of heparanase and/or selectins
to be tested as a potential antimetastatic treatment.
In the present study, we tested novel semisynthetic hexasaccharide
compounds for their capacity to inhibit heparanase and/or P-selectin
activities in vitro as well as experimental metastasis in vivo. For
this purpose, we have synthesized hexasaccharide mimics of malto-
hexaose sulfate in which a central glycosidic bond was substituted
by a hydrolase-resistant C-C bond. Maltohexaose sulfate was chosen
because of its bioequivalence with phosphomannopentaose sulfate
(PI-88), a potent carbohydrate-based heparanase inhibitor currently
Figure 1. Structures and preferred conformation of STMCα,α and STMCα,β.
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being subjected to phase 2/3 clinical trials in cancer patients [36].
The sugar chains of these compounds are characterized by the pres-
ence of an interglycosidic C-C bond expected to confer chemical and
metabolic stability compared with malto-oligosaccharides.
Materials and Methods
Preparation of Compounds
Halo-sugars’ electroreduction on silver cathode has been used to
prepare double sugar units cancelled through the formation of stable
interglycosidic C-C bonds. This procedure is accompanied by the
loss of a halide anion from an electrochemically reduced halo-sugar,
and the radical reactivity dictates the statistic distribution of prod-
ucts with formation of α,α: α,β: β,β C-C bonds (1:2:1) [37,38].
Tri-maltose C-C–linked dimers TMCα,α and TMCα,β were
prepared by acetobromomaltotriose electrochemical reduction fol-
lowed by deacetylation [39]. Sulfation of TMCα,α and TMCα,β
was performed by addition of 590 mg of sulfur trioxide pyridine
complex (3.68 mmol, 10 Eq/Eq –OH) to a pyridine solution of
TMC (0.0185 mmol, 4 × 10−3 M), resulting in STMCα,α and
STMCα,β, respectively (Figure 1). The reaction mixture was
warmed to 80°C and stirred for 6 hours, avoiding moisture with a
CaCl2 trap. The mixture was cooled down to room temperature,
neutralized with a saturated solution of NaHCO3, and exhaustively
evaporated under vacuum. The solid residue was dissolved in water
and separated on TSK column. STMCα,α and STMCα,β were fully
characterized by NMR analysis (E. Vismara et al., unpublished data).
Cell Lines and Reagents
Mouse colon carcinoma cell line MC-38 stably expressing GFP,
MC-38GFP [17], and mouse melanoma cell line B16-BL6 [8] were
grown in Dulbecco modified Eagle medium supplemented with 10%
fetal calf serum (Invitrogen, Carlsbad, CA). Human colon carcinoma
cells LS180 (ATCC, Manassas, VA) were grown in α-minimum es-
sential medium (Invitrogen) supplemented with 10% fetal calf serum
(Invitrogen). All reagents were from Sigma (St. Louis, MO) unless
otherwise stated.
Mice
Wild-type C57BL/6J mice were obtained from The Jackson Lab-
oratory (Bar Harbor, ME). All experiments were performed in accor-
dance with the guidelines of the Animal Care and Use Committee of
the Zürich Center for Integrative Human Physiology.
Inhibition of P-selectin
Ability of STMCs to inhibit adhesion of LS180 cells to immobi-
lized P-selectin was examined as described previously [34]. Briefly, an
ELISA plate (Nunc, Rochester, NY), coated overnight with soluble
Protein A, was blocked with 1% bovine serum albumin in Hank’s
balanced salt solution for 30 minutes at room temperature and incu-
bated with mouse P-selectin chimera (400 ng/well) for 3 hours at
room temperature. Calcein AM–labeled LS180 tumor cells were
added to the plate in the presence or absence of serially diluted
STMCs at concentrations ranging from 0.58 to 500 μg/ml. After
1 hour of incubation while rotating at 4°C, adherent cells were quanti-
fied bymeasuring the fluorescence with a GENios ELISA reader (Tecan,
Männedorf, Switzerland). The half-maximal inhibitory concentration
(IC50) values were calculated from three independent experiments.
Coagulation Assays
Automatic determination of partial thromboplastin time (PTT)
of samples was performed in duplicates by mixing pooled normal
plasma with PTT reagent (FSL actin; Dade Behring, Deerfield,
IL). After 10 minutes, the clotting time was determined on a Sysmex
CA-1500 analyzer (Diamond Diagnostics, Holliston, MA). Photo-
metric determination of anti-Xa activity was performed to evaluate
the activity of STMCs in human plasma on Sysmex CA-1500 ana-
lyzer, using the LMWH Kit (Chromogenics, MöIndal, Sweden).
Heparanase Activity Assay
Preparation of sulfate-labeled extracellular matrix (ECM)–coated
dishes and determination of heparanase enzymatic activity were per-
formed as described in detail elsewhere [40,41]. STMCs were tested
for their ability to inhibit heparanase, as previously described [33].
Figure 2. (A) Selectin inhibitory activity of C-C hexasaccharides.
The ability of STMCα,α and STMCα,β hexasaccharides to inhibit
P-selectin–mediated adhesion of LS-180 human colon carcinoma
cells was compared to that of unfractionated heparin as described
in Materials and Methods. Data are representative of three indepen-
dent experiments. (B) Bioavailability of STMCα,β in vivo. Platelet
adhesion to intravenously injected MC-38GFP cells was analyzed
in mice receiving STMCα,β and compared to PBS-injected mice.
The number of tumor cells positive for platelet staining was deter-
mined in lungs from mice killed at 30 minutes, 3 hours, or 7 hours
after injection as described inMaterials andMethods. The difference
in platelet/tumor cell association between control-injected mice
(PBS) and STMCα,β-injected mice was found to be statistically sig-
nificant at 30 minutes and 3 hours by one-way ANOVA (P < .001).
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Briefly, sulfate-labeled ECM coating the surface of 35-mm culture
dishes was incubated (4 hours, 37°C, pH 6.0) with constitutively ac-
tive (GS3) [42] recombinant human heparanase (120 ng/ml) in the
absence or presence of 5 μg/ml of each STMCs. The incubation
medium containing sulfate-labeled degradation fragments was sub-
jected to gel filtration on a Sepharose CL-6B column. Fractions
(0.2 ml) were eluted with PBS, and their radioactivity was counted
in a β-scintillation counter. Degradation fragments of HS side chains
were eluted at 0.5 < Kav < 0.8 (peak II, fractions 15-35). Nearly in-
tact heparan sulfate proteoglycan (HSP) was eluted just after the Vo
(Kav < 0.2, peak I, fractions 3-12). We have previously demonstrated
that labeled fragments eluted in peak II are degradation products of
HS because they were 1) fivefold to sixfold smaller than intact HS
side chains, 2) resistant to further digestion with papain and chondroi-
tinase ABC, and 3) susceptible to deamination by nitrous acid [40].
Platelet–Tumor Cell Aggregation In Vivo
C57BL/J6 mice were killed at various time points after intrave-
nous injection of tumor cells, and frozen lungs sections were incubated
with anti-CD41 antibody (Becton Dickinson, Mountain View, CA),
followed by detection with goat antirat antibody conjugated with
Alexa568 (Invitrogen) as described [34]. The extent of platelet–tumor
cell association was quantified in 20 view fields (40× magnifications)
by immunofluorescence microscopy.
Experimental Metastasis
C57BL/J6 wild-type mice were intravenously injected with 300,000
MC-38GFP cells or B16-BL6 melanoma cells [43]. Some mice re-
ceived 150 μg of STMCs 10 minutes before tumor cell injection. Mice
injected with B16-BL6 melanoma cells were killed after 14 days, and
the number of lung metastatic foci was counted. Mice injected with
MC-38GFP cells were killed after 28 days and macroscopically evalu-
ated. Metastatic burden in the lungs was determined by measurements
of GFP in the lung homogenate [17].
Results
Sulfated Hexasaccharides as Potential Inhibitors of Metastasis
Modified heparins that block P-selectin and/or heparanase have
been tested as potential inhibitors of metastasis [10,33]. We aimed
at synthesizing small oligosaccharide structures endowed with inhib-
itory activity of P-selectin and/or heparanase and testing their thera-
peutic potential in mouse models of metastasis.
Figure 3. Heparanase and anticoagulant activity of STMCs. (A and B) Anticoagulant activity. STMCs were tested for effect on PTT (A) and
anti-Xa activity (B) as described in Materials and Methods. Shown are the results obtained with STMCα,β. Same results were obtained
with STMCα,α. Data are representative of three independent determinations, and the variation did not exceed ±10% of the mean. (C)
Heparanase inhibitory activity. The ability of STMCα,α and STMCα,β hexasaccharides to inhibit recombinant heparanase enzymatic ac-
tivity was determined as described in Materials and Methods. Data are representative of three independent experiments.
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Halo-monosaccharides electroreduction on silver cathode allows
dimerization of a carbon-centered radical and affords C-disaccharide
mimics [38]. By extending this technique to oligosaccharides, we suc-
ceeded in preparing sulfated tri-maltose C-C–linked dimers STMCα,α
and STMCα,β (Figure 1). A detailed description of the synthetic pro-
cedure is provided elsewhere [38].
STMCs Inhibit P-selectin Binding in a
Linkage-Specific Manner
Attenuation of metastasis in the absence of P-selectin or its in-
hibition by native and chemically modified heparins has been docu-
mented in a number of animal models [10,16,34,44]. To investigate
C-C–linked hexasaccharides as potential inhibitors of P-selectin, we
tested the ability of both STMCα,α and STMCα,β to inhibit adhe-
sion of LS-180 colon carcinoma cells to immobilized P-selectin [10].
STMCα,β showed a good inhibitory activity of P-selectin (IC50
150 μg/ml), although less effective than unfractionated heparin (IC50
40 μg/ml) (Figure 2A). In contrast, STMCα,α exerted no P-selectin
inhibitory activity, indicating that change of the C-C linkage from
αα to αβ is critical for binding to P-selectin.
To determine an effective dose of STMCα,β for the metastasis ex-
periments, we first analyzed its bioavailability in vivo. Tumor cells
carrying selectin ligands are known to form tumor cell emboli medi-
ated primarily through platelet P-selectin [16,34]. We intravenously
injected 150 μg of STMCα,β 10 minutes before injection of MC-
38GFP mouse colon carcinoma cells. Mice were killed at different
time points between 30 minutes and 7 hours after injection, and
the extent of platelet–tumor cell association was quantified (Fig-
ure 2B). Approximately 80% of tumor cells in the lung tissue of
PBS-injected mice were associated with platelets at all times. Injec-
tion of STMCα,β reduced platelet aggregation on tumor cells to
approximately 40% during the first 3 hours, but there was no inhi-
bition at later time points (5 and 7 hours). These results indicate that
STMCα,β is biologically active for at least 3 hours after tumor injec-
tion and is relatively rapidly cleared from the circulation.
Anticoagulant Activity of STMCs
Both compounds STMCα,α and STMCα,β exhibited a high,
dose dependent anticoagulant activity (PTT, at 10 μg/ml comparable
to that of 0.5 U heparin), but were devoid of anti-Xa activity (Fig-
ure 3, A and B).
STMCs Effectively Inhibit Heparanase Enzymatic Activity
Heparanase activity is associated with cancer progression in a va-
riety of cancers and its inhibition by heparin derivatives attenuates
tumor growth and metastasis [2–5,9,12]. Using a naturally produced
sulfate-labeled ECM as a substrate [40,41], we tested the ability of
both STMCα,α and STMCα,β to inhibit heparanase enzymatic ac-
tivity. As demonstrated in Figure 3C , compound STMCα,β was
more effective than compound STMCα,α, yielding 85% and 58%
inhibition by 5 μg/ml, respectively.
STMCs Attenuate Metastasis Primarily by Inhibition
of P-selectin
To determine the ability of STMCs to attenuate metastasis, we
intravenously injected wild-type mice with 150 μg/mouse of STMC
followed by injection of B16-BL6 melanoma cells 10 minutes later.
B16-BL6 cells were shown to express P-selectin ligands as well as sig-
nificant amounts of heparanase [10]. Heparanase-specific STMCα,α
reducedmetastasis by ∼65%,whereas the P-selectin–specific STMCα,β,
which inhibits both P-selectin and heparanase, was more effective,
yielding 82% inhibition (Figure 4). Next, we tested both STMCs
in the MC-38GFP colon carcinoma model [10,17]. Intravenous in-
jection of STMCs was followed by injection of MC-38GFP cells,
and mice were killed after 28 days (Figure 5). The P-selectin–
specific STMCα,β attenuated metastasis to similar levels as ob-
served with P-selectin–deficient mice [10,17], whereas STMCα,α
had no effect, in agreement with the little or no heparanase activity
observed in MC-38 colon carcinoma cells [10]. Taken together,
these findings indicate that the newly synthesized hexasaccharides
effectively attenuated experimental metastasis by targeting P-selectin
and that inhibition of heparanase enzymatic activity is a valid ap-
proach in heparanase-expressing tumor cells.
Discussion
Several studies have shown that the antimetastatic activity of heparin is
based on its ability to inhibit heparanase and selectins [23,33,34,45].
The bioactive moieties of natural polysaccharides reside in specific or
Figure 4. C-C hexasaccharides attenuate metastasis of B16-BL6
melanoma cells. (A) Mice were intravenously injected with 150 μg
of STMCα,α or STMCα,β 10 minutes before injection of 3 × 105
B16-BL6 cells. Fourteen days after injection mice were killed, and
the lungs were dissected and evaluated for the number of meta-
static foci/lung. Statistical significance was determined by one-
way ANOVA (P < .001). (B) Representative images of lungs derived
from mice injected with STMCα,α or STMCα,β versus control (PBS).
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unspecific oligosaccharides mostly consisting of more than four carbo-
hydrate units [46]. Owing to their small molecular size, oligosaccha-
rides are expected to have enhanced bioavailability than their polymeric
precursors. These considerations led to isolation of sequences from
natural oligosaccharides and development of glycan mimetics hav-
ing the capacity to inhibit heparanase or selectins [47–49]. Sulfated
maltohexaose has been identified to be an efficient inhibitor of tumor
growth and metastasis, primarily because of inhibition of heparanase
[47]. PI-88, a mixture of highly sulfated oligosaccharides, reached
phase 3 clinical development for hepatocellular carcinoma. A new
class of heparanase-inhibiting HS mimetics based on anomerically
pure, fully sulfated oligosaccharides was recently optimized for anti-
cancer drug development [49]. In the case of selectin inhibitors, the
early developments of sialyl Lewis X–based glycan mimetics has been
replaced by development of nonglycoside small molecule inhibitors
[50]. In the present work, we tested semisynthetic sulfated malto-
oligosaccharides for their potential to inhibit heparanase and P-selectin.
These glycan mimetics are characterized by the presence of an inter-
glycosidic C-C bond, which, similar to other C-glycosides that are
less vulnerable to metabolic processing than their O-analogs, is ex-
pected to confer improved chemical and metabolic stability relative
to malto-oligosaccharides [51]. Molecular modeling and conforma-
tional analysis have shown that the interglycosidic C-C bond modifies
the geometry of the sugar chains, increasing their conformation ri-
gidity [39]. Whereas STMCα,β was found to be an effective inhibitor
of P-selectin, the conformational change to STMCα,α completely
eliminated its selectin binding activity (Figure 2A), emphasizing the
high specificity of this interaction. In contrast, both STMCs inhib-
ited heparanase enzymatic activity, the αβ configuration being more
effective (Figure 3C ), indicating a less restricted specificity for inter-
action with heparanase compared with selectins. Because the confor-
mational flexibility of oligosaccharides is critical for their binding to
proteins and, consequently, for their bioactivity [52], our observations
provide evidence that a rigid C-C structures defines the specificity of
selectin binding.
STMCs effectively attenuated metastasis in both the B16 mela-
noma and MC-38 colon carcinoma systems (Figures 4 and 5). Be-
cause the heparanase-specific STMCα,α did not affect metastasis of
MC-38GFP carcinoma cells expressing no heparanase (Figure 5),
tumor-derived heparanase, as opposed to heparanase contributed
by other blood-borne cells (i.e., neutrophils, platelets), seems to be
critical for metastasis in this experimental setting [10]. STMCα,β
that efficiently inhibits P-selectin was a better inhibitor of lung col-
onization by B16-BL6 melanoma and MC-38GFP carcinoma cells
than STMCα,α (Figure 5). Likewise, modified heparins endowed
with P-selectin–inhibitory activity effectively attenuated metastasis,
to an extent similar to that observed in P-selectin–deficient mice
[10,22,23,53]. The rapid cell surface expression of P-selectin on
platelets and endothelial cells on activation makes P-selectin one of
the earliest molecules mediating cell adhesion [54,55]. Accumulating
evidence indicates that P-selectin–mediated interactions contribute
to cancer progression (reviewed in Laubli and Borsig [55,56] and
Ludwig et al. [57]). Yet, the recently developed specific selectin inhib-
itors are being tested only in different inflammatory situations such
as ischemia-reperfusion injury, atherosclerosis, and deep vein throm-
bosis [50,58]. Here, we provide evidence that sulfated mannose–based
hexasaccharides (STMCα,β) specifically inhibit P-selectin and thereby
attenuate experimental metastasis (Figure 5). Thus, STMCα,β rep-
resents one of the smallest glycan-based selectin inhibitor that is ac-
tive in vivo.
High heparanase expression by multiple myeloma cells is associated
with enhanced bone metastasis [6] and modified non–anticoagulant
glycol-split heparins endowed with heparanase inhibitory activity have
been shown to effectively attenuate myeloma tumor growth and bone
metastasis [10,28]. Similarly, inhibition of heparanase either by mod-
ified heparins [10] or by the newly developed STMCs hexasaccha-
rides (Figure 4) attenuated metastasis, further confirming the critical
involvement of heparanase in metastasis. Importantly, the heparin-
derived compounds effectively inhibited xenograft tumor growth and
spontaneous metastasis of human myeloma [9,28] and sarcoma [59].
Synthesis of STMCs is being scaled up to enable their evaluation in
the same systems.
Non–anticoagulant heparin–derived inhibitors of metastasis have
been developed and tested in a number of laboratories (reviewed
in Casu et al. [60], Borsig [61], and Kragh and Loechel [62]). How-
ever, heparin-based inhibitors exhibit a limited bioavailability and
poor pharmacokinetics in vivo. Unlike heparin, the synthetic hexasac-
charides (STMCs) presented in this work represent stable, small size
Figure 5. Experimental metastasis of MC-38 colon carcinoma cells is efficiently attenuated by STMCα,β endowed with selectin inhibitory
activity. C57BL/J6 mice were intravenously injected with 150 μg of STMCα,β 10 minutes before injection of 3 × 105 MC-38GFP cells and
killed 28 days later. (A) The number of metastatic foci/lung representing initial metastatic seeding of tumor cells was counted. (B) The
extent of lung colonization was quantified by measurement of GFP fluorescence in lung homogenates. Statistical difference was found
only for the STMCα,β compound as determined by t test (P < .001).
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single entity oligosaccharides, expected to be more readily optimized
for drug development in terms of target (e.g., selectin vs heparanase)
specificity and bioavailability. Notably, the therapeutic potential of
compounds targeting heparanase and/or selectins is not restricted
to cancer, taking into account their involvement in inflammatory dis-
eases [63–65] and renal dysfunction [66].
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